Skip to main content

Table 3 Clinical and preclinical data related to anti-FGL1 therapy

From: Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Number Year Type of tumor Human/mouse/cell line Name of FGL1 antibody Conclusions References
1 2021 PDAC Cell lines FGL1 antibody, (Proteintech) Anti-FGL1 was associated with lipid metabolism and cell growth in PDAC [115]
2 2021 HCC Cell lines FGL1 antibody, (Proteintech) Anti-FGL1 eliminated resistance to sorafenib in HCC cells [116]
3 2020 NSCLC Cell lines ab197357 (Abcam) Anti-FGL1 increased the sensitivity of NSCLC cells to gefitinib [114]
4 2019 Murine colon adenocarcinoma Cell lines and mouse model Anti-mouse FGL1 (clone 177R4) Both anti-FGL1 and anti-LAG3 mAbs significantly controlled the growth of tumors derived from the MC38 murine colon that were inoculated into syngeneic C57BL/6 mice [50]
5 2019 Murine liver cell Cell lines and mouse model   Both anti-FGL1 and anti-LAG3 mAbs significantly controlled the growth of tumors derived from established Hepa1-6 murine liver cell lines that were inoculated into syngeneic C57BL/6 mice  
  1. HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma